SCHEMBL4925352

SCHEMBL4925352

NC1CCCCC1NC=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 5/20 0.48
ADH1A P07327 5/20 0.48
ADH1C P00326 4/20 0.48
ADH7 P40394 3/20 0.48
ADH4 P08319 2/20 0.46
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
THRB P10828 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ANPEP P15144 1/20 0.38
ERAP2 Q6P179 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13572438 1.00 ADH1B (0.48) ADH1BADH1AADH1CADH7ADH4
SCHEMBL14594135 1.00 ADH1B (0.48) ADH1BADH1AADH1CADH7ADH4
SCHEMBL15314039 0.82 ADH1A (0.60) ADH1BADH1AADH1CADH7ADH4
SCHEMBL798471 0.82 ADH1A (0.60) ADH1BADH1AADH1CADH7ADH4
SCHEMBL798497 0.76 ADH1A (0.60) ADH1BADH1AADH1CADH7ADH4
SCHEMBL19659669 0.76 THRB (0.41) MMP2MMP9CA12CA1CA2
SCHEMBL18165084 0.72
SCHEMBL12643894 0.72
SCHEMBL12643897 0.72
SCHEMBL1766842 0.71 ADH1B (0.48) ADH1BADH1AADH1CADH7ADH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109153635-A Neuropeptide S receptor (NPSR) agonist 研究三角协会 2019-01-04 CN disclosed
US-20080319019-A1 Therapeutic Agents ASTRAZENECA AB (SE) 2008-12-25 US disclosed
EP-1833802-A2 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006067428-A2 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319019-A1 Therapeutic Agents SDHA, GPR119, ABAT ADH1B 370/4885ADH1A 253/4885ADH1C 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.